These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12151430)

  • 41. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation.
    Ganor-Paz Y; Friedler-Mashiach Y; Ghetler Y; Hershko-Klement A; Berkovitz A; Gonen O; Shulman A; Wiser A
    J Endocrinol Invest; 2016 Jul; 39(7):799-803. PubMed ID: 26797707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women.
    Park WI; Kim SS; Chung HR; Shin SY; Lee JY
    Fertil Steril; 2004 Apr; 81(4):1067-72. PubMed ID: 15066465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Appropriate prolongation of GnRH-a down-regulation improves the synchronism of follicular development].
    Wang B; Sun HX; Liu JY; Hu YL; He FF
    Zhonghua Nan Ke Xue; 2011 Dec; 17(12):1087-91. PubMed ID: 22235676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced in vitro fertilization of human oocytes correlates with raised circulating FSH levels during ovarian stimulation in normogonadotropic women downregulated with GnRH-analogues.
    Andersen CY; Westergaard LG; Byskov AG; Erb K
    J Assist Reprod Genet; 1997 Nov; 14(10):581-8. PubMed ID: 9447458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation.
    Sullivan MW; Stewart-Akers A; Krasnow JS; Berga SL; Zeleznik AJ
    J Clin Endocrinol Metab; 1999 Jan; 84(1):228-32. PubMed ID: 9920089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
    Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
    European and Middle East Orgalutran Study Group
    Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of high basal FSH/LH ratio in women with normal FSH levels on in vitro fertilization outcomes.
    Lyu SW; Kim JW; Choi CH; Seok HH; Yoon TK; Kim A
    Gynecol Endocrinol; 2013 May; 29(5):424-9. PubMed ID: 23544714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate.
    Yding Andersen C; Bungum L; Nyboe Andersen A; Humaidan P
    Reprod Biomed Online; 2011 Aug; 23(2):187-95. PubMed ID: 21665546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles.
    Ferrari B; Pezzuto A; Barusi L; Coppola F
    Eur J Obstet Gynecol Reprod Biol; 2006 Jan; 124(1):70-6. PubMed ID: 16183188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outlook: who needs LH in ovarian stimulation?
    Alviggi C; Clarizia R; Mollo A; Ranieri A; De Placido G
    Reprod Biomed Online; 2006 May; 12(5):599-607. PubMed ID: 16790105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The LH endocrine profile in gonadotropin-releasing hormone analogue cycles.
    Janssens L; Roelant E; De Neubourg D
    Gynecol Endocrinol; 2022 Oct; 38(10):831-839. PubMed ID: 36039025
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.